Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

Asandeutertinib is a derivative of Tagrisso designed to avoid certain toxic side effects in patients with EGFR-mutated NSCLC.

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line treatment.

A trial of Incyte's Pemazyre in patients with FGFR-altered brain cancer did not meet its primary endpoint but had encouraging secondary outcomes.

The approval was based on results from a Phase IIb trial demonstrating a 15.5-month median overall survival on Ziihera.

The firm saw an improvement in progression-free survival for patients on the ivonescimab regimen and a trend toward improved overall survival.

A patient participating in the Phase III MAGNITUDE trial of nex-z experienced asymptomatic grade 4 liver transaminase elevations, the firm reported.

Due to financial, logistical, and regulatory barriers, only two in 10 patients eligible for CAR T-cell therapy in the US ...

The firm submitted data showing that more than 70 percent of patients with HER2-mutated NSCLC who hadn't received anti-HER2 therapy responded to sevabertinib.

The approval was based on results from the Phase II HORIZON-Lung trial, in which the treatment had a median progression-free survival of 11.5 months.

The firm is hoping to show in studies that its test can identify prostate cancer patients at low risk of recurrence who can receive less aggressive therapy.